| Wissenschaftl. Titel | A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Assess the Efficacy and Safety of Epcoritamab (GEN3013, DuoBody®-CD3×CD20) Plus Lenalidomide or Epcoritamab Alone as First-line Therapy in Anthracycline- Ineligible Subjects With Diffuse Large B-cell Lymphoma |
| Erkrankung |
Haema:
NHL: diffuses, großzelliges B-Zell-Lymphom:
Erstlinie
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (EudraCT) |
erstellt 30.12.2024 Data entry III CCP
geändert 30.12.2024 Data entry III CCP